BioSpace News Archive

Relay Therapeutics, Inc. announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2.

Bolt Biotherapeutics, Inc. announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

Terns Pharmaceuticals, Inc. announced that the TERN-701 trial-in-progress abstract is now available on the 2023 American Society of Clinical Oncology Annual Meeting website.

Regeneron Pharmaceuticals, Inc. announced updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab in patients with heavily pre-treated, relapsed/refractory multiple myeloma.

SpringWorks Therapeutics, Inc. announced that additional data from the Phase 3 DeFi trial assessing the impact of nirogacestat, an investigational gamma secretase inhibitor, on pain, tumor volume and T2 hypersensitivity in adults with desmoid tumors will be presented at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2-6, 2023.

Genprex, Inc. announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA® Immunogene Therapy in combination with Tagrisso® in late-stage non-small cell lung cancer were published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago, IL and online.

Theseus Pharmaceuticals, Inc. announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors.

Pionyr Immunotherapeutics, Inc. announced that PY159, a monoclonal antibody targeting TREM1, was well-tolerated with signals of durable therapeutic activity in a Phase 1a dose-escalation study as a single agent and in combination with pembrolizumab.